在首次静脉瘤后接受OAC治疗的成年人中,NSAID使用与增加出血风险有关
1University of Michigan, Ann Arbor, Michigan, USA (G.B.).
Annals of internal medicine
|March 31, 2025
概括
这项研究引入了一般内科,家庭医疗和全科医疗的新型公式,以及血液学方面的具体进展. 这些临床影响评级为评估医疗实践的有效性提供了一种新的定量方法.
科学领域:
- 一般的内科医学一般内科医学.
- 家庭练习 家庭练习
- 一般的做法一般的做法
- 血液学 血液学 血液学
背景情况:
- 目前的临床影响评估缺乏标准化的定量指标.
- 需要在初级保健和血液学等专业领域改进评估工具.
研究的目的:
- 开发和介绍新的定量公式来评估临床影响.
- 为评估一般内科,家庭医疗,全科医疗和血液学方面的有效性提供一个框架.
主要方法:
- 基于[公式:参见文本]的新数学公式的开发.
- 将这些公式应用于特定的临床领域,包括血液学.
主要成果:
- 对GIM/FP/GP和血液学的公式被成功导出,并以[公式:参见文本]形式呈现.
- 拟议的指标提供了可量化的临床影响的衡量标准.
结论:
- 引入的配方提供了一种标准化的方法,用于评估各种医学学科的临床影响.
- 这些定量工具可以帮助评估医疗保健中的绩效和质量改善举措.
相关概念视频
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
316
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
316
Esophageal Varices-II: Clinical Features and Management
31
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
31
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
339
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
339
Peptic Ulcer Disease IV: Management
54
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
54
Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
Drugs for Treatment of Ulcerative Colitis in IBD
110
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
110


